Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results

BACKGROUND: Dimethyl fumarate (DMF) demonstrated favorable benefit–risk in relapsing-remitting multiple sclerosis (RRMS) patients in phase-III DEFINE and CONFIRM trials, and ENDORSE extension. OBJECTIVE: The main aim of this study is assessing DMF safety/efficacy up to 13 years in ENDORSE. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Gold, Ralf, Arnold, Douglas L, Bar-Or, Amit, Fox, Robert J, Kappos, Ludwig, Mokliatchouk, Oksana, Jiang, Xiaotong, Lyons, Jennifer, Kapadia, Shivani, Miller, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978463/
https://www.ncbi.nlm.nih.gov/pubmed/34465252
http://dx.doi.org/10.1177/13524585211037909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978463/
https://www.ncbi.nlm.nih.gov/pubmed/34465252
http://dx.doi.org/10.1177/13524585211037909

Ejemplares similares